Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Allievex Corp.
Headquarters: Marblehead, MA, United States of America
Website: https://www.allievex.com
Year Founded: N/A
Status: Archived
BioCentury | Mar 1, 2024
Product Development
Rare disease spotlight: enzyme replacement therapy for the brain
At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Feb 29, 2024
Regulation
Ultrarare inflection point: stakeholders argue for biomarker-based approvals
Reagan-Udall Foundation meeting on biomarkers could change FDA policy on neuronal MPS endpoints, unleash approvals
BioCentury | Nov 13, 2019
Finance
Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets
Why Pappas created Allievex to shepherd an MPS IIIB program and other ultra-orphan assets
BioCentury | Oct 24, 2019
Finance
Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets
Why Pappas created Allievex to shepherd an MPS IIIB program and other ultra-orphan assets
Items per page:
1 - 4 of 4